

JOHN MARK JOYCE, M.D.
CNS HEALTHCARE OF JACKSONVILLE

April 8, 2024

Affiliation	<p>Investigator Clinical Neuroscience Solutions, Inc. 5200 Belfort Road, Suite 420, Jacksonville, FL 32256 2003 – Present</p> <p>Investigator Clinical Neuroscience Solutions, Inc. 5200 Belfort Road, Suite 175, Jacksonville, FL 32256 2021 – Present</p> <p>Investigator Clinical Neuroscience Solutions, Inc. 8823 San Jose Blvd Ste. 209, Jacksonville, FL 32217 2021 – present</p>
Clinical Trial Experience and Interest	<p>2003-Present Principal Investigator on over 200 phase II – IV clinical trials in children, adults, and geriatrics.</p> <p>Sleep Disorders, Chronic Pain, Osteoarthritis, Smoking Cessation, Alcohol Dependence, Substance Use Disorders, Migraine, Alzheimer’s Disease, Rheumatologic Disorders, Skin Disorders, Women’s Health, Attention Deficit Hyperactivity Disorder, Autism, Mood Disorders, Obesity, Binge Eating Disorder, Bipolar Disorder, Dementia, Diabetes, Diabetic Peripheral Neuropathy, Diverticulitis, Fatigue, Female Sexual Arousal Disorder, Gambling, Anxiety Disorders, Gout, Hot Flashes, Hypertension, Irritable Bowel Syndrome, Mild Cognitive Impairment, Obsessive-Compulsive Disorder, Fibromyalgia, Oppositional Defiant Disorder, Panic Disorder, Post Traumatic Stress Disorder, Schizophrenia, Sexual Dysfunction, Social Phobia, Stuttering, Vulvar & Vaginal Atrophy, Chronic Idiopathic Constipation, Opioid Induced Constipation, Asthma, COPD, Flu Treatment, Down Syndrome, Post Herpetic Neuralgia and Hyperlipidemia, Uterine Fibroids, Hot Flashes, Pediatric Migraine & Pediatric Tourette’s. Hypertriglyceridemia, Atopic Dermatitis, Adolescent IBS, C-Diff Vaccine, Obesity, Type 1 Diabetes and UTI, Borderline Personality Disorder, Endometriosis, COVID-19 Vaccine, Postpartum Depression, Alopecia, Essential Tremors, CMV Vaccine, Psoriasis</p>
Professional Training and Experience	<p>1988 -1989 Internal Medicine and Neurology Internship, Emory University School of Medicine, Atlanta GA</p> <p>1989 – 1992 Psychiatry Residency, Emory University School of Medicine, Atlanta, GA</p> <p>1991-1992 Chief Resident, Department of Psychiatry, Grady Memorial Hospital, Atlanta, GA</p> <p>1992-2000 Private Practice, Atlanta, GA</p> <p>1992 – 1996 Consultant, Gwinnett/Rockdale/Newton Recover Center</p> <p>1996 – 2000 Medical Director, Gwinnett/Rockdale/Newton Recovery Center</p> <p>2001-2006 Director of Psychiatric Services, Duval County Pretrial Detention Center</p> <p>2001- Present Private Practice, Jacksonville, FL</p>

CNS Healthcare Jacksonville - 5200 Belfort Road, Suite 420, Jacksonville, Florida 32256

Tel: (904) 281-5757 Fax: (904) 281-5758 Mobile (904) 654-6451

www.cnshealthcare.com/Jacksonville

mjoyce@cnshealthcare.com

JOHN MARK JOYCE, M.D.
CNS HEALTHCARE OF JACKSONVILLE

April 8, 2024

Education	<p>1980-1984 B.S., Birmingham Southern College Department of Psychology Birmingham, AL</p> <p>1984-1988 M.D., University of Alabama School of Medicine Birmingham, AL</p>
License/ Accreditation	American Board of Psychiatry and Neurology
Industry Contacts	<p>Abbott Laboratories, Acadia, Acasti Pharma, Actavis, Addrenex, Aevi, Alcobra, Alder, Alkermes, Allergan, Allon, Alto Alynlyam, Alza, Amgen, Amylyx, AOBiome, Aptinyx, Arbor, Arena, Array, Astellas, AstraZeneca, Avanir, Axial Therapeutics, Axsome, Bayer, Biohaven, Bionomics, BlackThorn, Boehringer-Ingelheim, Bristol-Myers, Cassava Sciences, Cephalon, Cerecor,, Cingulate, Colucid, Corium, Daiichi Sanko, Dare Bioscience, Depomed, Dermavant, Dr. Reddy's, Edgemont, Eisai, Eli Lilly, Emalex, EmpowerPharm Inc, Engrail Therapeutics,,Ergomed,Evelo,Forest, Furiex, Galderma, Genomind, GlaxoSmithKline,Hihghlightll Pharma,Honeybrains, Impax, Mitsubishi & Neurocrine Biosciences, Impel Indevus, Intarcia, Integrium Clinical Research, Intracellular, IronShore,Nestle Health Science, Johnson & Johnson, KemPharm, Labopharm, Labry's, Lumos Labs, Lundbeck, Mass General, Merck, Medgenics, Medimmune,Mineralys, Mithra, MSI, Mylan and Paratek Pharmaceuticals,Neumora, Neuralstem, NeuroPharma, New River Pharmaceuticals, NLS Pharma,Noema, Novartis, Noven, NovoNordisk, ObSeva, ONO, Oramed, Organon, Ortho-McNeil, Otsuka, Palatin, Palatin, Pfizer, PGxHealth, Praxis Medicines, Purdue, Regeneron, Roche, Romark, Sage Therapeutics, Sanofi, Satsuma, Sepracor, Shionogi, Shire, Sirtsei, Sorrento, Squibb, Sunovion, Suzhou Connect, Synergy, Takeda,Tal Medical., Targacept, TauRX, TEVA, Tonix, Versanis Bio,Vertex, Wyeth,AssureRx, VibrantVirios Therapeutics, VistaGen Therapeutics,</p>
Original Articles	<p>McCallum, D.M., McCallum, R., Gurwitch, R.H., & Joyce, J.M. (1986). Assessing Perceptions of Dental Health Behaviors. <i>Clinical Preventative Dentistry</i>, 8, 27-30.</p> <p>Hughes, T.A., Moore, M.A, Joyce, J.M., Go, R.C.P, Segrest, J.P. & Blackwell, T. (1992). Sexual Differences in Lipoprotein Composition in Dyslipidemic Hypertension with Premature Atherosclerosis: Deficiency of HDL-I and HDL-M "A-I Alone" Particle. <i>Journal of Laboratory and Clinical Medicine</i>, 119(1).</p> <p>Weisler, R., Joyce, J.M, McGill, L., Lazarus, A., Szamosi, J., Eriksson, H. (2009). Extended Release Quetiapine Fumarate Monotherapy for Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo-Controlled Study. <i>CNS Spectr.</i> 2009; 14(6):299-313.</p> <p>El-Khalili N., Joyce M., Atkinson S., Buynak R. J., Datto C., Lindgren P., Eriksson H., Extended – Release Quetiapine Fumarate (Quetiapine XR) as Adjunctive Therapy in Major Depressive Disorder (MDD) in Patients with an Inadequate Response to Ongoing Antidepressant Treatment: A Multicentre, Randomized, Double-Blind, Placebo Controlled Study. <i>International Journal of Neuropsychopharmacology</i>, Vol 23:1-16, February 2010.</p>

CNS Healthcare Jacksonville - 5200 Belfort Road, Suite 420, Jacksonville, Florida 32256

Tel: (904) 281-5757 Fax: (904) 281-5758 Mobile (904) 654-6451

www.cnshealthcare.com/Jacksonville

mjoyce@cnshealthcare.com

Abstracts

Joyce, M., Khan, A., Atkinson, S., Eggens, I., Baldytcheva, I., Brecher, M., (2007). Efficacy and Safety of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients with Generalized Anxiety Disorder (GAD). American Psychiatric Association Convention.

Khan, A., Joyce, M., Atkinson, S., Eggens, I., Baldytcheva, I., Brecher, M. (2007). Efficacy and Safety of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients with Generalized Anxiety Disorder (GAD). Anxiety Disorders Association of America, 28th Annual Conference.

El-Khalili, N., Joyce, M., Atkinson, S., Buynak, R., Datto, C., Lindgren, P., Eriksson, H., Brecher, M., (2007). Adjunctive Extended Release Quetiapine Fumarate (Quetiapine XR) in Patients with Major Depressive Disorder and Inadequate Antidepressant Response. American Psychiatric Association Convention.

Weisler, R., Joyce, M., McGill, L., Lazarus, A., Schollin, M., Brecher, M., (2007). Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy for Major Depressive Disorder (MDD): A Double-Blind Placebo Controlled Study.

Hughes, T.A., Moore, M.A., Joyce, J.M., Go, R.C.P, Segrest, J.P., & Blackwell, T. (1998). Family with Hypertiglyceridemia and Premature Atherosclerosis: "Light ApoA-1" Deficiency. *Atherosclerosis*, 8, 578a.